Freshfields Advised Abbvie On Its Exclusive Licensing Agreement With Remegen
Freshfields Advised Abbvie On Its Exclusive Licensing Agreement With Remegen
Global law firm Freshfields advised AbbVie on its exclusive licensing agreement with RemeGen for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody. RC148 is currently being developed by RemeGen as a monotherapy and in combination regimens across multiple advanced solid tumors.
Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize RC148 outside of the Greater China territory. RemeGen will receive an upfront payment of USD $650 million and is eligible to receive up to USD $4.95 billion in aggregate development, regulatory, and commercial milestone payments, along with tiered, double-digit royalties on net sales outside the Greater China territory.
The Freshfields team was led by Kristen Riemenschneider (Partner), and included Jake Silvers (Senior Associate), and Shannon O’Hara (Associate), Jimmy Cao (Associate), and Richard Bird (Partner), Ma Ya (Counsel), Fan Li (Senior Associate), and Yichen Xing (Associate), Tiffany Lam (Associate), and Leslie Xu (Legal Consultant), provided support on China matters. Brock Dahl (Partner), and Christine Chong (Senior Associate), advised on U.S. data privacy matters. Daniel Cendan (Partner), and Jennifer King (Associate), advised on healthcare compliance matters.
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.
